Positron Corp (POSC) 0.0047 $POSC
Telik Receives $1.5 Million National Cancer Institute Contract to Develop Novel Antibody-based PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Aug 25, 8:30AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has received a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the preclinical work being conducted by MabVax, together with its collaboration partner, Memorial Sloan-Kettering Cancer Center (MSKCC) to develop a novel Positron Emission Tomography (PET) imaging agent for detection and assessment of pancreatic cancer.
PET Imaging Systems Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
PRWeb - Fri Aug 22, 8:05AM CDT
Positron emission tomography (PET) is a functional three dimensional imaging technique based on detection of photons originating from the destruction of emitted positrons with electrons from surrounding tissue. The imaging system produces a three-dimensional image of functional processes in the body. PET involves labeling of biomolecules with positron emitters also known as neutron deficient nuclei. As such, the whole body distribution of positron-emitting biomarkers in the whole body can be imaged with high sensitivity with the use of PET imaging system. Three-dimensional images of tracer concentration within the body are then constructed by computer analysis making PET imaging ideal for understanding biological events and biodistribution of radio labeled drugs non-invasively in animals. Though medical imaging is dominated by anatomical imaging such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US), functional imaging modalities including positron emission tomography (PET) have been demonstrated to be of particular value in a number of disease staging and follow-up regimens. Positron Emission Tomography (PET) uses short-lived radionuclides to produce high definition 3D images of functional processes in vivo.
Breast Imaging Technologies Market Worth $3 Billion by 2019 - New Report by MarketsandMarkets
PRWeb - Mon Aug 18, 7:07AM CDT
The report "Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019" analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
Global Positron Emission Tomography Market: Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
PRWeb - Sun Aug 10, 8:01AM CDT
Positron emission tomography (PET) is a nuclear medicine imaging procedure that is used to monitor various internal body organs and tissues in order to identify certain disease conditions. PET imaging procedure provides a better insight about the working condition of organs and tissues, size, shape and position. PET is most widely used by oncologists in order to diagnose various types of cancer; neurologists in order to diagnose neurological disorders and cardiologists in order to diagnose cardiovascular diseases. Ongoing developments in this area are likely to begin its use in other specialties as well. This is also performed in order to assess the progress of the treatment of certain diseases. This procedure is different from magnetic resonance imaging (MRI) and computed tomography (CT) as they only show the tissue structure and blood flow to and from organs. This imaging procedure is also being used in combination with other diagnostic technologies such as CT with an aim to provide more precise information about various neurological, cardiovascular and cancer diseases.
Breast Imaging Technologies Market worth $3 Billion by 2019
M2 - Mon Aug 04, 3:17AM CDT
The report "Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019" analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging...) - Global Forecasts to 2019
PR Newswire - Mon Jul 21, 8:05AM CDT
Reportbuyer.com has added a new market research report:
Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019
M2 - Mon Jul 21, 3:08AM CDT
Report Description
Global Cytogenetics Report 2014 - Technologies, Markets and Companies to 2023
M2 - Fri Jul 18, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bc7wtb/cytogenetics) has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering. The report includes summary profiles of 67 companies relevant to cytogenetics along with their 74 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified.The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. Technologies encompassed within molecular imaging include optical imaging, magnetic resonance imaging (MRI) and nuclear medicine techniques. Positron emission tomography (PET) is the most sensitive and specific technique for imaging molecular pathways in vivo in humans. Cytogenetics can be refined by application of cytogenetics at single molecule level. Nanotechnology has facilitated the development of technology for single molecule imaging. Atomic force microscope (AFM) has become a well-established technique for imaging single biomolecules under physiological conditions. The scanning probe microscope (SPM) system is emerging as an increasingly important tool for non-intrusive interrogation of biomolecular systems in vitro and have been applied to improve FISH. Another example of application of nanobiotechnology is QD (quantum dot)-FISH probes, which can detect down to the single molecule level. Key Topics Covered: Executive Summary 1. Introduction 2. Technologies used for cytogenetics 3. Fluorescent In Situ Hybridization 4. Genomic Technologies relevant to Cytogenetics 5. Molecular Imaging & Single Molecular Detection 6. Role of Nanobiotechnology in Cytogenetics 7. Biomarkers and Cytogenetics 8. Applications of Cytogenetics 9. Cancer Cytogenetics 10. Cytogenetics Markets 11. Companies 12. References For more information visit http://www.researchandmarkets.com/research/bc...togenetics Source: Jain PharmaBiotech
Sofie Biosciences Partners with PerkinElmer to Deliver Benchtop PET In Vivo Imaging Systems to Preclinical Research Professionals
PR Newswire - Fri Jun 13, 5:06AM CDT
Sofie Biosciences, a leader in the field of PET imaging, and PerkinElmer Inc., today announced an agreement in which PerkinElmer will exclusively commercialize and sell preclinical Positron Emission Tomography (PET) - X-Ray and 3-dimensional Computed Tomography (CT) imaging systems developed by, or in conjunction with, Sofie Biosciences.
United Kingdom Nuclear Imaging Equipment Market Outlook to 2020
M2 - Mon Mar 24, 3:52AM CDT
Summary
Research and Markets: United States Nuclear Imaging Equipment Market Outlook to 2020
Business Wire - Thu Mar 20, 1:29PM CDT
Research and Markets (http://www.researchandmarkets.com/research/czfwn8/united_states) has announced the addition of the "United States Nuclear Imaging Equipment Market Outlook to 2020" report to their offering.
United States Nuclear Imaging Equipment Market 2020 Forecasts in New Research Report at RnRMarketResearch.com
PRWeb - Thu Mar 20, 11:04AM CDT
This report provides key market data on the United States Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems).
United States Nuclear Imaging Equipment Market Outlook to 2020
M2 - Thu Mar 20, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jckjng/united_states) has announced the addition of the "United States Nuclear Imaging Equipment Market Outlook to 2020" report to their offering. "United States Nuclear Imaging Equipment Market Outlook to 2020", provides key market data on the United States Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Nuclear Imaging Equipment market wherever available. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Nuclear Imaging Equipment Market, United States 3.1 Nuclear Imaging Equipment Market, United States, Revenue ($m), 2005-2012 3.2 Nuclear Imaging Equipment Market, United States, Revenue ($m), 2012-2020 3.3 Nuclear Imaging Equipment Market, United States, Volume (Units), 2005-2012 3.4 Nuclear Imaging Equipment Market, United States, Volume (Units), 2012-2020 3.5 Nuclear Imaging Equipment Market, United States, Average Price ($), 2005-2020 3.6 Nuclear Imaging Equipment Market, United States, Distribution Share by Revenue ($m), 2011-2012 3.7 Nuclear Imaging Equipment Market, United States, Company Share by Revenue ($m), 2011-2012 4 Overview of Key Companies in United States, Nuclear Imaging Equipment Market 5 Nuclear Imaging Equipment Market Pipeline Products 6 Financial Deals Landscape 6.1 Acquisition 6.2 Asset Transactions 6.3 Equity Offerings 6.4 Partnerships 7 Recent Developments 7.1 Corporate Communications 7.2 Financial Announcements 7.3 Government and Public Interest 7.4 Other Significant Developments 7.5 Strategy And Business Planning 8 Appendix Companies Mentioned Philips Healthcare GE Healthcare Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/jc...ted_states
New Partnership Agreement with the National Association of Attorneys General
M2 - Tue Feb 25, 6:25AM CST
Ambassador William R. Brownfield, Assistant Secretary of State for the Bureau of International Narcotics and Law Enforcement Affairs (INL), signed a partnership agreement today with Attorney General J.B. Van Hollen of Wisconsin, President of the National Association of Attorneys General (NAAG). Under this partnership, NAAG's National Attorneys General Training and Research Institute and INL will cooperate on advancing the development of rule-of-law institutions with partner countries around the world.
Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica
Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
PR Newswire - Tue Feb 11, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70--percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS). These data further support the potential of OMS824 to have a high therapeutic index in the treatment of patients with schizophrenia, Huntington's disease and other cognitive disorders. Omeros is completing a Phase 2a trial evaluating the drug in patients with schizophrenia and will start enrollment in a Phase 2 trial for Huntington's disease this quarter.
Cytogenetics Report - Technologies, Markets and Companies - 2014
M2 - Mon Feb 10, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/m53hk3/cytogenetics) has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering. This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. Technologies encompassed within molecular imaging include optical imaging, magnetic resonance imaging (MRI) and nuclear medicine techniques. Positron emission tomography (PET) is the most sensitive and specific technique for imaging molecular pathways in vivo in humans. Cytogenetics can be refined by application of cytogenetics at single molecule level. Nanotechnology has facilitated the development of technology for single molecule imaging. Atomic force microscope (AFM) has become a well-established technique for imaging single biomolecules under physiological conditions. The scanning probe microscope (SPM) system is emerging as an increasingly important tool for non-intrusive interrogation of biomolecular systems in vitro and have been applied to improve FISH. Another example of application of nanobiotechnology is QD (quantum dot)-FISH probes, which can detect down to the single molecule level. There are connections between cytogenetics and biomarkers of genetic disorders as well as cancer. Biomarkers are very important for molecular diagnostics. Not only are molecular diagnostic technologies used for discovery of biomarkers, biomarkers are the basis of several diagnostics. As a means to understand pathomechanism of disease and as links between diagnostics and therapeutics, biomarkers are playing a role in development of personalized medicine. Application of cytogenetics extend beyond genetic disorder and cancer to diagnosis of several other diseases. Other important applications are drug discovery, and development of personalized medicine. The chapter on markets provides a global perspective of the cytogenetics business in the major markets: US, Western Europe (including France, Germany, Italy, Spain, and the UK), and Japan. The total figures for the market are also broken out according to the technologies and major disease areas in which they are applied. Markets figure are given for the year 2013 and estimates are made for the years 2018 and 2023. Advantages and limitations of various technologies have been pointed out throughout the report but this chapter includes SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis of some of the competing technologies including the following: conventional FISH, innovative FISH technologies, PCR-based assays, and single molecule imaging. Unfulfilled needs in cytogenetics market are depicted graphically. Among various technologies, FISH is most advanced and less opportunities for further development than single molecule detection, which is in infancy and has more future potential. Key Topics Covered: Executive Summary 1. Introduction 2. Technologies used for cytogenetics 3. Fluorescent In Situ Hybridization 4. Genomic Technologies relevant to Cytogenetics 5. Molecular Imaging & Single Molecular Detection 6. Role of Nanobiotechnology in Cytogenetics 7. Biomarkers and Cytogenetics 8. Applications of Cytogenetics 9. Cancer Cytogenetics 10. Cytogenetics Markets 11. Companies 12. References For more information visit http://www.researchandmarkets.com/research/m5...togenetics Source: Jain PharmaBiotech
Telik Receives $1.5 Million National Cancer Institute Contract to Develop Novel Antibody-based PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Aug 25, 8:30AM CDT
Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has received a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the preclinical work being conducted by MabVax, together with its collaboration partner, Memorial Sloan-Kettering Cancer Center (MSKCC) to develop a novel Positron Emission Tomography (PET) imaging agent for detection and assessment of pancreatic cancer.
PET Imaging Systems Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
PRWeb - Fri Aug 22, 8:05AM CDT
Positron emission tomography (PET) is a functional three dimensional imaging technique based on detection of photons originating from the destruction of emitted positrons with electrons from surrounding tissue. The imaging system produces a three-dimensional image of functional processes in the body. PET involves labeling of biomolecules with positron emitters also known as neutron deficient nuclei. As such, the whole body distribution of positron-emitting biomarkers in the whole body can be imaged with high sensitivity with the use of PET imaging system. Three-dimensional images of tracer concentration within the body are then constructed by computer analysis making PET imaging ideal for understanding biological events and biodistribution of radio labeled drugs non-invasively in animals. Though medical imaging is dominated by anatomical imaging such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US), functional imaging modalities including positron emission tomography (PET) have been demonstrated to be of particular value in a number of disease staging and follow-up regimens. Positron Emission Tomography (PET) uses short-lived radionuclides to produce high definition 3D images of functional processes in vivo.
Breast Imaging Technologies Market Worth $3 Billion by 2019 - New Report by MarketsandMarkets
PRWeb - Mon Aug 18, 7:07AM CDT
The report "Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019" analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
Global Positron Emission Tomography Market: Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
PRWeb - Sun Aug 10, 8:01AM CDT
Positron emission tomography (PET) is a nuclear medicine imaging procedure that is used to monitor various internal body organs and tissues in order to identify certain disease conditions. PET imaging procedure provides a better insight about the working condition of organs and tissues, size, shape and position. PET is most widely used by oncologists in order to diagnose various types of cancer; neurologists in order to diagnose neurological disorders and cardiologists in order to diagnose cardiovascular diseases. Ongoing developments in this area are likely to begin its use in other specialties as well. This is also performed in order to assess the progress of the treatment of certain diseases. This procedure is different from magnetic resonance imaging (MRI) and computed tomography (CT) as they only show the tissue structure and blood flow to and from organs. This imaging procedure is also being used in combination with other diagnostic technologies such as CT with an aim to provide more precise information about various neurological, cardiovascular and cancer diseases.
Breast Imaging Technologies Market worth $3 Billion by 2019
M2 - Mon Aug 04, 3:17AM CDT
The report "Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019" analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging...) - Global Forecasts to 2019
PR Newswire - Mon Jul 21, 8:05AM CDT
Reportbuyer.com has added a new market research report:
Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019
M2 - Mon Jul 21, 3:08AM CDT
Report Description
Global Cytogenetics Report 2014 - Technologies, Markets and Companies to 2023
M2 - Fri Jul 18, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bc7wtb/cytogenetics) has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering. The report includes summary profiles of 67 companies relevant to cytogenetics along with their 74 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified.The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. Technologies encompassed within molecular imaging include optical imaging, magnetic resonance imaging (MRI) and nuclear medicine techniques. Positron emission tomography (PET) is the most sensitive and specific technique for imaging molecular pathways in vivo in humans. Cytogenetics can be refined by application of cytogenetics at single molecule level. Nanotechnology has facilitated the development of technology for single molecule imaging. Atomic force microscope (AFM) has become a well-established technique for imaging single biomolecules under physiological conditions. The scanning probe microscope (SPM) system is emerging as an increasingly important tool for non-intrusive interrogation of biomolecular systems in vitro and have been applied to improve FISH. Another example of application of nanobiotechnology is QD (quantum dot)-FISH probes, which can detect down to the single molecule level. Key Topics Covered: Executive Summary 1. Introduction 2. Technologies used for cytogenetics 3. Fluorescent In Situ Hybridization 4. Genomic Technologies relevant to Cytogenetics 5. Molecular Imaging & Single Molecular Detection 6. Role of Nanobiotechnology in Cytogenetics 7. Biomarkers and Cytogenetics 8. Applications of Cytogenetics 9. Cancer Cytogenetics 10. Cytogenetics Markets 11. Companies 12. References For more information visit http://www.researchandmarkets.com/research/bc...togenetics Source: Jain PharmaBiotech
Sofie Biosciences Partners with PerkinElmer to Deliver Benchtop PET In Vivo Imaging Systems to Preclinical Research Professionals
PR Newswire - Fri Jun 13, 5:06AM CDT
Sofie Biosciences, a leader in the field of PET imaging, and PerkinElmer Inc., today announced an agreement in which PerkinElmer will exclusively commercialize and sell preclinical Positron Emission Tomography (PET) - X-Ray and 3-dimensional Computed Tomography (CT) imaging systems developed by, or in conjunction with, Sofie Biosciences.
United Kingdom Nuclear Imaging Equipment Market Outlook to 2020
M2 - Mon Mar 24, 3:52AM CDT
Summary
Research and Markets: United States Nuclear Imaging Equipment Market Outlook to 2020
Business Wire - Thu Mar 20, 1:29PM CDT
Research and Markets (http://www.researchandmarkets.com/research/czfwn8/united_states) has announced the addition of the "United States Nuclear Imaging Equipment Market Outlook to 2020" report to their offering.
United States Nuclear Imaging Equipment Market 2020 Forecasts in New Research Report at RnRMarketResearch.com
PRWeb - Thu Mar 20, 11:04AM CDT
This report provides key market data on the United States Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems).
United States Nuclear Imaging Equipment Market Outlook to 2020
M2 - Thu Mar 20, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jckjng/united_states) has announced the addition of the "United States Nuclear Imaging Equipment Market Outlook to 2020" report to their offering. "United States Nuclear Imaging Equipment Market Outlook to 2020", provides key market data on the United States Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Positron Emission Tomography Systems (PET Systems and PET/CT Systems) and Single Photon Emission Computed Tomography Systems (SPECT Systems and SPECT/CT Systems). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Nuclear Imaging Equipment market wherever available. Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases). Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Nuclear Imaging Equipment Market, United States 3.1 Nuclear Imaging Equipment Market, United States, Revenue ($m), 2005-2012 3.2 Nuclear Imaging Equipment Market, United States, Revenue ($m), 2012-2020 3.3 Nuclear Imaging Equipment Market, United States, Volume (Units), 2005-2012 3.4 Nuclear Imaging Equipment Market, United States, Volume (Units), 2012-2020 3.5 Nuclear Imaging Equipment Market, United States, Average Price ($), 2005-2020 3.6 Nuclear Imaging Equipment Market, United States, Distribution Share by Revenue ($m), 2011-2012 3.7 Nuclear Imaging Equipment Market, United States, Company Share by Revenue ($m), 2011-2012 4 Overview of Key Companies in United States, Nuclear Imaging Equipment Market 5 Nuclear Imaging Equipment Market Pipeline Products 6 Financial Deals Landscape 6.1 Acquisition 6.2 Asset Transactions 6.3 Equity Offerings 6.4 Partnerships 7 Recent Developments 7.1 Corporate Communications 7.2 Financial Announcements 7.3 Government and Public Interest 7.4 Other Significant Developments 7.5 Strategy And Business Planning 8 Appendix Companies Mentioned Philips Healthcare GE Healthcare Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/jc...ted_states
New Partnership Agreement with the National Association of Attorneys General
M2 - Tue Feb 25, 6:25AM CST
Ambassador William R. Brownfield, Assistant Secretary of State for the Bureau of International Narcotics and Law Enforcement Affairs (INL), signed a partnership agreement today with Attorney General J.B. Van Hollen of Wisconsin, President of the National Association of Attorneys General (NAAG). Under this partnership, NAAG's National Attorneys General Training and Research Institute and INL will cooperate on advancing the development of rule-of-law institutions with partner countries around the world.
Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica
Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
PR Newswire - Tue Feb 11, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70--percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS). These data further support the potential of OMS824 to have a high therapeutic index in the treatment of patients with schizophrenia, Huntington's disease and other cognitive disorders. Omeros is completing a Phase 2a trial evaluating the drug in patients with schizophrenia and will start enrollment in a Phase 2 trial for Huntington's disease this quarter.
Cytogenetics Report - Technologies, Markets and Companies - 2014
M2 - Mon Feb 10, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/m53hk3/cytogenetics) has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering. This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. Technologies encompassed within molecular imaging include optical imaging, magnetic resonance imaging (MRI) and nuclear medicine techniques. Positron emission tomography (PET) is the most sensitive and specific technique for imaging molecular pathways in vivo in humans. Cytogenetics can be refined by application of cytogenetics at single molecule level. Nanotechnology has facilitated the development of technology for single molecule imaging. Atomic force microscope (AFM) has become a well-established technique for imaging single biomolecules under physiological conditions. The scanning probe microscope (SPM) system is emerging as an increasingly important tool for non-intrusive interrogation of biomolecular systems in vitro and have been applied to improve FISH. Another example of application of nanobiotechnology is QD (quantum dot)-FISH probes, which can detect down to the single molecule level. There are connections between cytogenetics and biomarkers of genetic disorders as well as cancer. Biomarkers are very important for molecular diagnostics. Not only are molecular diagnostic technologies used for discovery of biomarkers, biomarkers are the basis of several diagnostics. As a means to understand pathomechanism of disease and as links between diagnostics and therapeutics, biomarkers are playing a role in development of personalized medicine. Application of cytogenetics extend beyond genetic disorder and cancer to diagnosis of several other diseases. Other important applications are drug discovery, and development of personalized medicine. The chapter on markets provides a global perspective of the cytogenetics business in the major markets: US, Western Europe (including France, Germany, Italy, Spain, and the UK), and Japan. The total figures for the market are also broken out according to the technologies and major disease areas in which they are applied. Markets figure are given for the year 2013 and estimates are made for the years 2018 and 2023. Advantages and limitations of various technologies have been pointed out throughout the report but this chapter includes SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis of some of the competing technologies including the following: conventional FISH, innovative FISH technologies, PCR-based assays, and single molecule imaging. Unfulfilled needs in cytogenetics market are depicted graphically. Among various technologies, FISH is most advanced and less opportunities for further development than single molecule detection, which is in infancy and has more future potential. Key Topics Covered: Executive Summary 1. Introduction 2. Technologies used for cytogenetics 3. Fluorescent In Situ Hybridization 4. Genomic Technologies relevant to Cytogenetics 5. Molecular Imaging & Single Molecular Detection 6. Role of Nanobiotechnology in Cytogenetics 7. Biomarkers and Cytogenetics 8. Applications of Cytogenetics 9. Cancer Cytogenetics 10. Cytogenetics Markets 11. Companies 12. References For more information visit http://www.researchandmarkets.com/research/m5...togenetics Source: Jain PharmaBiotech
